Can Non-HLA Single Nucleotide Polymorphisms Help Stratify Risk in TrialNet Relatives at Risk for Type 1 Diabetes?
Andrea K Steck, Ping Xu, Susan Geyer, Maria J Redondo, Peter Antinozzi, John M Wentworth, Jay Sosenko, Suna Onengut-Gumuscu, Wei-Min Chen, Stephen S Rich, Alberto Pugliese
The Journal of Clinical Endocrinology & Metabolism | ENDOCRINE SOC | Published : 2017
Awarded by Eunice Kennedy Shriver National Institute of Child Health and Human Development
Awarded by American Diabetes Association
Awarded by NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES
This study was sponsored by the Type 1 Diabetes TrialNet Pathway to Prevention Study Group, which is a clinical trials network funded by the NIH through the National Institute of Diabetes and Digestive and Kidney Diseases, the National Institute of Allergy and Infectious Diseases, and The Eunice Kennedy Shriver National Institute of Child Health and Human Development, through the cooperative agreements U01 DK061010, U01 DK061034, U01 DK061042, U01 DK061058, U01 DK085465, U01 DK085453, U01 DK085461, U01 DK085463, U01 DK085466, U01 DK085499, U01 DK085504, U01 DK085505, U01 DK085509, U01 DK103180, U01DK103153, U01-DK085476, U01-DK103266, and the JDRF. A. K. S. was supported by the American Diabetes Association Grant 1-14-CD-17. J. M. W. was supported by aMentored Clinical Researcher Fellowship from JDRF Australia.